Early and accurate diagnosis, which relies on laboratory tests and imaging exams, is essential for treatment and management and significantly reduces the morbidity rate. However, diagnosis of the syndrome is challenging, especially due to the variability in the signs and symptoms and the lack of consensus amongst healthcare professionals. Similarities to other conditions, as well as normal pregnancy features, commonly lead to misdiagnosed cases or more often, delayed diagnosis. There is a general consensus regarding the main three diagnostic criteria of<unk> , which include hepatic dysfunction, thrombocytopenia and microangiopathic haemolytic anaemia in patients suspected to have preeclampsia. * A blood smear will often exhibit abnormalities, such as schistocytes, bur cells, and helmet cells, which indicate erythrocyte damage. * Thrombocytopenia, which is the earliest coagulopathy present in all<unk>  patients, is indicated by low platelet count (below 100 x 109 L-1) or by testing the levels of fibrin metabolites and antithrombin III. * Elevated serum levels of certain proteins, in particular, LDH, alanine transaminase (ALT) and aspartate transaminase (AST), are indicative of hepatic dysfunction. Extremely high serum levels of these proteins, specifically LDH levels > 1,400 IU/L, AST levels > 150 IU/L and ALT levels > 100 IU/L, significantly elevate the risk of maternal mortality. A number of other, but less conclusive, clinical diagnostic criteria are also used in diagnosis alongside the main clinical diagnostic criteria for<unk> . * De novo manifestation of hypertension with systolic pressure and diastolic pressure above 160mmHg and 110 mmHg, respectively. * Proteinuria, leucocytosis and elevated uric acid concentrations > 7.8 mg. * Decreased serum haptoglobin and haemoglobin levels. * Increased serum bilirubin levels and visual disturbances. Imaging tests, such as ultrasound, tomography or magnetic resonance imaging (MRI), are instrumental in the correct diagnosis of<unk>  in patients with suspected liver dysfunction. Unurgent cases must undergo MRI, but laboratory tests, such as glucose determination, are more encouraged in mild cases of<unk> . Classification A classification system, which was developed in Mississippi, measures the severity of the syndrome using the lowest observed platelet count in the patients alongside the appearance of the other two main clinical criteria. Class I is the most severe, with a relatively high risk of morbidity and mortality, compared to the other two classes. * Class I<unk>  is characterised by a platelet count below 50,000/µL. * Class II<unk>  is characterised by a platelet count of 50,000-100,000/µL. * Class III<unk>  is characterised by a platelet count of 100,000-150,000/µL. Another classification system, introduced in Memphis, categorises<unk>  based on its expression. * Partial expression of the condition is characterised by the manifestation of one or two of the main diagnostic criteria. * The complete expression of the condition is characterised by the manifestation of all three main diagnostic criteria.
HELLP syndrome
Thrombotic thrombocytopenic purpura
Acute fatty liver of pregnancy
Viral hepatitis
Primrose syndrome
Ascending cholangitis
Antiphospholipid syndrome
Hemolytic–uremic syndrome